Compare NVNI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVNI | ALXO |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 79.7M |
| IPO Year | N/A | 2020 |
| Metric | NVNI | ALXO |
|---|---|---|
| Price | $3.60 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 165.7K | ★ 267.7K |
| Earning Date | 09-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,250,627.00 | N/A |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | $15.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1491.58 | N/A |
| 52 Week Low | $1.44 | $0.40 |
| 52 Week High | $121.90 | $2.27 |
| Indicator | NVNI | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 55.40 |
| Support Level | $3.32 | $1.29 |
| Resistance Level | $3.00 | $1.57 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 60.27 | 83.75 |
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.